Labcorp Holdings Inc. (LH) | Rumor.io

Labcorp Holdings

Attention (50-day avg)0%

Attention rank (50-day avg)#1,698

Bullish sentiment (50-day avg)24%

Price to earnings ratio25.6

Market capitalization25.1B

Earnings per share12.1

Dividend yield (TTM)0.93%

Revenue (annual)14B

Net income (annual)877.7M

Social

What share of all stock conversation is about LH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Feb 17

Labcorp (LH) reported Q4 revenue of $3.52B, missing estimates by $39.9M, but EPS of $10.2 exceeded estimates by $0.12.
The company expects full-year 2026 enterprise revenue of $14.61B to $14.79B, with a midpoint growth of 5.4%, and adjusted EPS guided to $17.55 to $18.25.
Labcorp's revenue growth is slowing, with FY 2025 revenue growth of 7.2% and 2026 enterprise guidance of 4.7% to 6.0%, with a midpoint deceleration to ~5.4%.

Generated by AI

Sentiment

Of the messages about LH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	71.43% +52.68	84.64% -2.23
Bearish	—	—	28.57% -52.68	15.36% +2.23

Bullish· Jul 25

Labcorp Holdings Inc. (LH) has seen a high volume breakout, indicating a potential price increase.
Multiple brokerages have upgraded their ratings on LH, with price targets ranging from $285 to $306, suggesting a strong outlook for the stock.
A long-term investor has reported a 29.39% realized gain on a position in LH, indicating the stock's potential for long-term growth.

Bearish· Apr 29

The stock is overvalued based on its financials, which are not relevant in the current market environment.
The stock is experiencing a bearish trend, with a potential drop to $180, and the author is expecting it to continue downward.
The stock's recent drop is not justified by its earnings, and the author believes it will continue to underperform, with no reason for it to move above $180.

Generated by AI

Topics

Of the messages about LH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	79.41%	89.86%
Earnings	—	—	2.94%	0.72%
Controversies	—	—	17.65%	0.27%
Analysts	—	—	0%	0.32%
Macro	—	—	0%	0.27%
Technical Analysis	—	—	0%	8.56%

Earnings· Apr 25

LabCorp reported Q1 2023 earnings of $3.82 per share, missing estimates of $3.96.
The company's revenue for the quarter was $3.78B, beating estimates of $3.7B.
LabCorp updated its FY23 guidance to adjusted EPS of $16.25 to $17.75, narrowing the range from its prior guidance.

Analysts· Jul 14

LabCorp (LH) upgraded to Buy from Neutral at BofA Securities with a target price of $220.
The upgrade was driven by a positive view on the company's growth prospects and its position in the healthcare testing market.
The new target price of $220 represents a potential upside of 15% from the current price.

Announcements· Feb 9

Labcorp Holdings Inc. ($LH) plans to spin off its wholly owned clinical development business in a tax-free transaction.
The spin-off business will be named Fortrea, a global CRO that will offer comprehensive drug and medical device development services.
Several Labcorp executives, including the CEO, CFO, and EVPs, have recently made insider trades, acquiring or selling securities in the company.

Generated by AI

Community

Of the messages about LH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	57.5%	15.25%
Newcomers	—	—	42.5%	84.75%

Regulars· Feb 17

Labcorp forecasts an upbeat annual profit due to strong demand for diagnostic products, leading to a 0.8% pre-market increase.
The company's Q4 EPS beats expectations, but growth decelerates, and 2026 guidance is described as tepid.
Morgan Stanley analysts say Labcorp's guidance "should be well received," citing the company's strong demand for diagnostic products.

Newcomers· Feb 17

Labcorp's Q4 2025 earnings report showed strong profitability, with Adjusted EPS rising 18% to $4.07, but top-line growth decelerated significantly to 5.6%.
The company's Q4 2025 revenue of $3.52B missed estimates by -39.9M, but EPS of $4.07 exceeded estimates by 0.12, with 195.65% YoY growth.
Labcorp's FY26 adjusted EPS guidance is above estimates, signaling strong forward momentum, with a projected 5.4% revenue increase in 2026 amid strategic transitions and operational momentum.

Generated by AI

News

Is This the Right Time to Add Labcorp Stock to Your Portfolio?

LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.

1d agoYahoo Finance

Labcorp Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains

5d agomarketwatch.com

Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors

6d agomarketwatch.com

Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy (NYSE:LH)

Labcorp dives on CMS 2027 Medicare lab-payment cuts; see why the selloff may be overdone, and the downside capped and why it’s a strong buy of LH stock—read now.

6d agoSeeking Alpha

Labcorp Holdings (LH) Eyes Acquisitions And Lab Tech Investment After 2026 Investor Day

Labcorp Holdings (NYSE:LH) used its 2026 Investor Day to outline a push into targeted acquisitions and new lab technologies. Management emphasized capital deployment toward advanced lab management systems and expanded digital experiences for patients and providers. The company highlighted plans to integrate acquired platforms with its existing diagnostic infrastructure to streamline operations and data handling. Labcorp's renewed focus on acquisitions and digital lab tools only tells part of...

7d agoYahoo Finance

Is Labcorp Holdings Stock Outperforming the Dow?

7d agoBarchart.com

Also Discussed

Investors talking about LH also mention

#	Name	Attention
1	Quest Diagnostics IncorporatedDGX	0%0
2	Qiagen N.V.QGEN	0%+0
3	Thermo Fisher Scientific Inc.TMO	0%0
4	HOLX - Hologic, Inc.	——
5	Myriad Genetics Inc.MYGN	0%0
6	Veracyte, Inc.VCYT	0%new
7	IQVIA Holdings Inc.IQV	0%0
8	Illumina Inc.ILMN	0%+0
9	QuidelOrtho CorporationQDEL	0%new
10	NVTA - Invitae Corporation	——

Labcorp Holdings Inc.

Healthcare
Diagnostics & Research

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support. Its Diagnostics Laboratories segment covers testing in areas such as oncology, women’s health, autoimmune disease, and neurology, while its Biopharma Laboratory Services segment supports pharmaceutical and biotech clients with laboratory capabilities for clinical trials and development programs. The company plays a key role in healthcare by helping customers generate data used in diagnosis, treatment decisions, and biomedical research.

Website

Location

531 South Spring Street

Burlington, NC, 27215

United States

Social

What share of all stock conversation is about LH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Feb 17

Labcorp (LH) reported Q4 revenue of $3.52B, missing estimates by $39.9M, but EPS of $10.2 exceeded estimates by $0.12.
The company expects full-year 2026 enterprise revenue of $14.61B to $14.79B, with a midpoint growth of 5.4%, and adjusted EPS guided to $17.55 to $18.25.
Labcorp's revenue growth is slowing, with FY 2025 revenue growth of 7.2% and 2026 enterprise guidance of 4.7% to 6.0%, with a midpoint deceleration to ~5.4%.

Generated by AI

Sentiment

Of the messages about LH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	71.43% +52.68	84.64% -2.23
Bearish	—	—	28.57% -52.68	15.36% +2.23

Bullish· Jul 25

Labcorp Holdings Inc. (LH) has seen a high volume breakout, indicating a potential price increase.
Multiple brokerages have upgraded their ratings on LH, with price targets ranging from $285 to $306, suggesting a strong outlook for the stock.
A long-term investor has reported a 29.39% realized gain on a position in LH, indicating the stock's potential for long-term growth.

Bearish· Apr 29

The stock is overvalued based on its financials, which are not relevant in the current market environment.
The stock is experiencing a bearish trend, with a potential drop to $180, and the author is expecting it to continue downward.
The stock's recent drop is not justified by its earnings, and the author believes it will continue to underperform, with no reason for it to move above $180.

Generated by AI

Topics

Of the messages about LH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	79.41%	89.86%
Earnings	—	—	2.94%	0.72%
Controversies	—	—	17.65%	0.27%
Analysts	—	—	0%	0.32%
Macro	—	—	0%	0.27%
Technical Analysis	—	—	0%	8.56%

Earnings· Apr 25

LabCorp reported Q1 2023 earnings of $3.82 per share, missing estimates of $3.96.
The company's revenue for the quarter was $3.78B, beating estimates of $3.7B.
LabCorp updated its FY23 guidance to adjusted EPS of $16.25 to $17.75, narrowing the range from its prior guidance.

Analysts· Jul 14

LabCorp (LH) upgraded to Buy from Neutral at BofA Securities with a target price of $220.
The upgrade was driven by a positive view on the company's growth prospects and its position in the healthcare testing market.
The new target price of $220 represents a potential upside of 15% from the current price.

Announcements· Feb 9

Labcorp Holdings Inc. ($LH) plans to spin off its wholly owned clinical development business in a tax-free transaction.
The spin-off business will be named Fortrea, a global CRO that will offer comprehensive drug and medical device development services.
Several Labcorp executives, including the CEO, CFO, and EVPs, have recently made insider trades, acquiring or selling securities in the company.

Generated by AI

Community

Of the messages about LH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	57.5%	15.25%
Newcomers	—	—	42.5%	84.75%

Regulars· Feb 17

Labcorp forecasts an upbeat annual profit due to strong demand for diagnostic products, leading to a 0.8% pre-market increase.
The company's Q4 EPS beats expectations, but growth decelerates, and 2026 guidance is described as tepid.
Morgan Stanley analysts say Labcorp's guidance "should be well received," citing the company's strong demand for diagnostic products.

Newcomers· Feb 17

Labcorp's Q4 2025 earnings report showed strong profitability, with Adjusted EPS rising 18% to $4.07, but top-line growth decelerated significantly to 5.6%.
The company's Q4 2025 revenue of $3.52B missed estimates by -39.9M, but EPS of $4.07 exceeded estimates by 0.12, with 195.65% YoY growth.
Labcorp's FY26 adjusted EPS guidance is above estimates, signaling strong forward momentum, with a projected 5.4% revenue increase in 2026 amid strategic transitions and operational momentum.

Generated by AI

Labcorp Holdings

Social

Feb 17

Bullish· Jul 25

Bearish· Apr 29

Earnings· Apr 25

Analysts· Jul 14

Announcements· Feb 9

Regulars· Feb 17

Newcomers· Feb 17

Is This the Right Time to Add Labcorp Stock to Your Portfolio?

Labcorp Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains

Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors

Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy (NYSE:LH)

Labcorp Holdings (LH) Eyes Acquisitions And Lab Tech Investment After 2026 Investor Day

Is Labcorp Holdings Stock Outperforming the Dow?

Also Discussed

Labcorp Holdings Inc.

Company Information

Location

Is This the Right Time to Add Labcorp Stock to Your Portfolio?

Labcorp Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains

Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors

Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy (NYSE:LH)

Labcorp Holdings (LH) Eyes Acquisitions And Lab Tech Investment After 2026 Investor Day

Is Labcorp Holdings Stock Outperforming the Dow?

Also Discussed

Social

Feb 17

Bullish· Jul 25

Bearish· Apr 29

Earnings· Apr 25

Analysts· Jul 14

Announcements· Feb 9

Regulars· Feb 17

Newcomers· Feb 17